These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 37260368)
1. Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany. Kröning H; Göhler T; Decker T; Grundeis M; Kojouharoff G; Lipke J; Semsek D; Moorahrend E; Sauer A; Bruch HR; Liersch R; Nusch A; Vehling-Kaiser U; Welslau M; Grunewald R; Harich HD; Stephany M; Uhlig J; de Buhr R; Frank M; Hogrefe C; Marschner N; Potthoff K; Hartmann F; Reisländer T; Schwaner I Int J Cancer; 2023 Sep; 153(6):1227-1240. PubMed ID: 37260368 [TBL] [Abstract][Full Text] [Related]
2. Subgroup analyses from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial. Karthaus M; Heinemann V; Riera-Knorrenschild J; Kretzschmar A; Welslau M; Kaiser U; Pelz H; Ettrich TJ; Held S; Kehmann L; Hess J; Reisländer T; Weiss L; BMC Cancer; 2024 Jul; 24(1):887. PubMed ID: 39044160 [TBL] [Abstract][Full Text] [Related]
3. Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study". Coutzac C; Trouilloud I; Artru P; Henriques J; Masson T; Doat S; Bouché O; Coriat R; Saint A; Moulin V; Vernerey D; Gallois C; De La Fouchardière C; Tougeron D; Taieb J Clin Colorectal Cancer; 2022 Jun; 21(2):132-140. PubMed ID: 35337742 [TBL] [Abstract][Full Text] [Related]
4. Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS). Hamers PAH; Vink GR; Elferink MAG; Stellato RK; Dijksterhuis WPM; Punt CJA; Koopman M; May AM; Clin Colorectal Cancer; 2022 Jun; 21(2):154-166. PubMed ID: 35474007 [TBL] [Abstract][Full Text] [Related]
5. Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G). Kito Y; Kawakami H; Mitani S; Nishina S; Matsumoto T; Tsuzuki T; Shinohara Y; Shimokawa H; Kumanishi R; Ohta T; Katsuya H; Kawakami T; Nishina T; Hasegawa H; Akiyoshi K; Chiba Y; Yamazaki K; Hironaka S; Muro K Oncologist; 2024 Mar; 29(3):e330-e336. PubMed ID: 37950903 [TBL] [Abstract][Full Text] [Related]
6. Comparative Efficacy and Safety of Standard and Biweekly Trifluridine/Tipiracil Regimen in Patients With Colorectal Cancer. Hara S; Sakai D; Ikemura K; Shintani T; Yamamoto T; Satoh T; Okuda M Anticancer Res; 2024 Mar; 44(3):1219-1226. PubMed ID: 38423630 [TBL] [Abstract][Full Text] [Related]
7. Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer. Van Cutsem E; Hochster H; Shitara K; Mayer R; Ohtsu A; Falcone A; Yoshino T; Doi T; Ilson DH; Arkenau HT; George B; Benhadji KA; Makris L; Tabernero J ESMO Open; 2022 Dec; 7(6):100633. PubMed ID: 36455504 [TBL] [Abstract][Full Text] [Related]
8. Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study. Shiroyama M; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Shimada Y; Esaki T; Makiyama A; Moriwaki T Sci Rep; 2023 Oct; 13(1):17931. PubMed ID: 37863951 [TBL] [Abstract][Full Text] [Related]
9. The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis. Sousa MJ; Gomes I; Pereira TC; Magalhães J; Basto R; Paulo J; Jacinto P; Bonito N; Sousa G Cancer Treat Res Commun; 2022; 31():100531. PubMed ID: 35172243 [TBL] [Abstract][Full Text] [Related]
10. Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan. Kagawa Y; Shinozaki E; Okude R; Tone T; Kunitomi Y; Nakashima M ESMO Open; 2023 Aug; 8(4):101614. PubMed ID: 37562196 [TBL] [Abstract][Full Text] [Related]
13. Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer. Kasper S; Kisro J; Fuchs M; Müller C; Schulz-Abelius A; Karthaus M; Rafiyan MR; Stein A BMC Cancer; 2018 Nov; 18(1):1124. PubMed ID: 30445951 [TBL] [Abstract][Full Text] [Related]
14. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer. Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008 [No Abstract] [Full Text] [Related]
15. Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial. Weiss L; Karthaus M; Riera-Knorrenschild J; Kretzschmar A; Welslau M; Vehling-Kaiser U; Pelz H; Ettrich TJ; Hess J; Reisländer T; Klein A; Heinemann V; ESMO Open; 2022 Feb; 7(1):100391. PubMed ID: 35149429 [TBL] [Abstract][Full Text] [Related]
16. Impact of KRAS Tabernero J; Taieb J; Fakih M; Prager GW; Van Cutsem E; Ciardiello F; Mayer RJ; Amellal N; Skanji D; Calleja E; Yoshino T ESMO Open; 2024 Mar; 9(3):102945. PubMed ID: 38471240 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS). Shitara K; Doi T; Hosaka H; Thuss-Patience P; Santoro A; Longo F; Ozyilkan O; Cicin I; Park D; Zaanan A; Pericay C; Özgüroğlu M; Alsina M; Makris L; Benhadji KA; Ilson DH Gastric Cancer; 2022 May; 25(3):586-597. PubMed ID: 34997449 [TBL] [Abstract][Full Text] [Related]
18. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer. van de Haar J; Ma X; Ooft SN; van der Helm PW; Hoes LR; Mainardi S; Pinato DJ; Sun K; Salvatore L; Tortora G; Zurlo IV; Leo S; Giampieri R; Berardi R; Gelsomino F; Merz V; Mazzuca F; Antonuzzo L; Rosati G; Stavraka C; Ross P; Rodriquenz MG; Pavarana M; Messina C; Iveson T; Zoratto F; Thomas A; Fenocchio E; Ratti M; Depetris I; Cergnul M; Morelli C; Libertini M; Parisi A; De Tursi M; Zanaletti N; Garrone O; Graham J; Longarini R; Gobba SM; Petrillo A; Tamburini E; La Verde N; Petrelli F; Ricci V; Wessels LFA; Ghidini M; Cortellini A; Voest EE; Valeri N Nat Med; 2023 Mar; 29(3):605-614. PubMed ID: 36864254 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial. Ilson DH; Tabernero J; Prokharau A; Arkenau HT; Ghidini M; Fujitani K; Van Cutsem E; Thuss-Patience P; Beretta GD; Mansoor W; Zhavrid E; Alsina M; George B; Catenacci D; McGuigan S; Makris L; Doi T; Shitara K JAMA Oncol; 2020 Jan; 6(1):e193531. PubMed ID: 31600365 [TBL] [Abstract][Full Text] [Related]
20. Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis. Tabernero J; Argiles G; Sobrero AF; Borg C; Ohtsu A; Mayer RJ; Vidot L; Moreno Vera SR; Van Cutsem E ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817131 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]